Latest news with #GLP1
Health Line
an hour ago
- Health
- Health Line
GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds
Researchers report that people taking GLP-1 drugs in daily life don't lose as much weight as those in clinical trials who take the same medications. The researchers add that people using weight loss drugs don't regain weight as quickly as those in clinical trials. One possible reason for the weight loss differential is that people in the 'real world' tend to stop taking these medications sooner than people in clinical trials. People who use commonly prescribed weight loss medications don't lose as much weight as participants in clinical trials, but they also don't regain weight as quickly. That's the conclusion of a new study published on June 10 in the journal Obesity. The study authors reported that the weight loss differential was mainly due to the fact that people tend to stop using GLP-1 drugs sooner than clinical trial participants. They also tend to use lower doses of these medications. The researchers also reported that A1C blood level reductions were similar for both groups of people. The researchers noted that they will initiate further research into what other measures, such as lifestyle changes or bariatric surgery, people may have adopted after discontinuing weight loss medications such as Wegovy and Zepbound. The researchers also want to look into why people stopped using weight loss drugs before their program regimen ended. 'Our findings indicate that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically meaningful weight reduction in patients who initiate obesity pharmacotherapy with semaglutide or tirzepatide,' the study authors wrote. 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight loss,' they added. 'Real world' use of weight loss medications For their study, researchers looked at the health records of 7,881 adults with obesity or weight management issues who did not have type 2 diabetes. Those people were seen between 2021 and 2023 at the Cleveland Clinic's facilities in Ohio and Florida. Their average age was about 51 years. Nearly 80% of the subjects were white. Of those participants, 6,109 were prescribed a weight loss medication such as Wegovy with the active ingredient semaglutide. The other 1,772 were prescribed a weight loss drug, such as Zepbound, with the active ingredient tirzepatide. About 80% of those subjects were given low doses of their weekly injectable weight loss medications. Researchers reported significant differences between people using weight loss medications in phase 3 clinical trials and those taking the drugs in the 'real world.' For starters, about half of those taking either medication in daily life stopped within the first 12 months. About 51% of those using a tirzepatide drug discontinued its use in that same time period. That compares with only 17% of semaglutide users and between 14% and 16% of tirzepatide users in clinical trials who quit during the first year. In addition, the average weight reduction for semaglutide participants in daily life was nearly 8% after one year while it was 12% for people taking tirzepatide. By comparison, the average weight loss in clinical trials was nearly 15% for semaglutide subjects as well as 15% for people on low dose tirzepatide and 20% for those on a higher dose of that medication. In general, weight loss was greater in people who took weight loss medications for a longer period of time. In addition, about 54% of people who had prediabetes at the start of their treatment plan improved to healthier A1C levels after one year. Around 3% of those studied progressed to type 2 diabetes after 12 months. Weight loss is a long-term commitment Mir Ali, MD, a surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the main takeaway from this study is that weight loss is a long-term commitment. Ali wasn't involved in the new study. 'The long-term use of medications is more effective than short-term use,' Ali told Healthline. 'The study confirms that obesity is a chronic condition like diabetes or hypertension.' Sarah Kim, MD, a professor of medicine at the University of California San Francisco, noted that discontinuing medication is common for people being treated for obesity and other conditions. Kim was likewise not involved in the new study. Kim added that adherence to medication schedules as well as diet and exercise programs isn't as easy in real life because people don't have the supervision and support a person gets during a clinical trial. 'Real life is different and results aren't always as spectacular as in clinical trials,' Kim told Healthline. Kim and Ali agreed that another reason people stop taking medications is that these drugs can be expensive, even if insurance is picking up part of the cost. There is also the fact that the side effects from these medications can be severe for some people. Plus, people in real life sometimes just get tired of the obligation of taking a pill or injecting themselves on a regular basis. Ali and Kim also noted that people need to realize that medications are only a tool to help them eat less. To lose weight and keep it off, a person needs to adopt lifestyle habits such as a healthy diet and regular exercise. 'The medications are not a short-term kickstart. They don't burn fat,' said Kim. 'The medications just help with the suppression of hunger.' 'The ultimate goal of the medications is to give people a tool to get them to a healthy weight,' Ali added. What to know about GLP-1 drug for weight loss Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and reduces hunger pangs. One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections. The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections. Previous studies have highlighted the effectiveness of these drugs on helping people lose weight. Past research has also indicated that these weight loss drugs can help lower a person's risk of cancer as well as provide benefits to heart health and brain health. Experts say the medications have proven to be effective and their use is likely to increase. 'This is a massive market and it's not going to go away,' Ali said. 'These medications are going to continue to be a big part of weight loss programs.'
News.com.au
6 hours ago
- Health
- News.com.au
Lizzo admits she tried Ozempic
The Good as Hell singer, who has been documenting her weight-loss journey on social media since 2023, revealed she had briefly dabbled with the GLP-1 agonist medication before deciding it was not for her. 'I tried everything," Lizzo, 37, told influencer Trisha Paytas on her Just Trish podcast. 'Ozempic works because you eat less food, yeah? So if you eat right, it makes you feel full. But if you can just do that on your own and get mind over matter, it's the same thing."
Yahoo
13 hours ago
- Health
- Yahoo
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight management and long-term wellness through a suite of integrated offerings. These include Health RX Telehealth™, Health RX Prescription Access™, and Health RX Wellness Support™, all accessible through its newly enhanced website at The update provides streamlined access to GLP-1 medications such as Ozempic®, Zepbound®, and compounded alternatives—subject to eligibility criteria and clinical discretion. The HealthRX platform is built to accommodate adults who are seeking a secure, doctor-supervised weight management option that minimizes barriers to care and supports routine-friendly wellness. A Digital Health Platform Designed for Results HealthRX offers a simplified path for adults to explore medically appropriate weight loss options from the comfort of home. Through the HealthRX intake process, users can connect with U.S.-licensed physicians to determine clinical eligibility for GLP-1 medications. The program emphasizes convenience and flexibility, removing the need for in-person consultations or insurance requirements. The platform's design integrates: Health RX Telehealth™ – Secure access to virtual consultations with board-certified physicians. Health RX Prescription Access™ – Direct, encrypted coordination with pharmacies for prescription fulfillment and renewals. Health RX Wellness Support™ – A collection of tools including coaching support, educational resources, medication reminders, and outcome tracking. Each service is built to align with common adult health goals—particularly those related to sustained weight management. Full details are available on the official HealthRX website at Highlight on GLP-1 Medication Access: Ozempic®, Zepbound®, and Tirzepatide Options GLP-1 medications have emerged as a physician-supervised option for individuals managing obesity or weight-related conditions. HealthRX facilitates access to FDA-approved GLP-1 treatments such as Ozempic®, Zepbound®, and Tirzepatide®, as well as compounded GLP-1 or GLP-1/GIP medications based on clinical suitability. These medications work by targeting appetite regulation and glucose control pathways and are prescribed in accordance with FDA labeling or compound-specific clinical judgment. The HealthRX platform outlines potential usage scenarios, average pricing tiers, and expected timelines for prescription delivery—all while emphasizing that outcomes vary by individual. For medication access information, visit HealthRX also confirms that compounded medications offered through the platform are prepared in U.S.-based facilities in accordance with USP <795> and <797> standards. The company notes that compounded drug products are not FDA-approved, and eligibility is determined during the virtual consultation process with a licensed provider. Three-Step Process Designed for Accessibility Visitors to the website are guided through a simple three-step intake process: Take the Assessment – Users begin by completing a short clinical questionnaire to determine preliminary eligibility. Meet a Board-Certified Physician – Within 24 hours, eligible users are connected to a licensed medical provider for an evaluation. Receive Medication – Upon approval, GLP-1 prescriptions are delivered securely to the patient's door with ongoing support available. This process is designed to make adult wellness and weight loss support accessible without long wait times, insurance hassles, or frequent office visits. A full description is provided at Pricing and Support Structure As listed on the platform: Ozempic® (Brand GLP-1) – $1,299/month (In Stock) Tirzepatide® (GLP-1 + GIP) – $1,299/month (Limited Stock) GLP-1 Injections (Compounded) – $189/month (Low Stock) GLP-1 Oral Tablets (Compounded) – $239/month (Low Stock) GLP-1 + GIP Injection (Compounded) – $349/month (In Stock) Pricing reflects bundled services that include medical evaluation, platform access, prescription coordination, and support. Details and plan tiers are explained at Transparent Clinical Oversight All HealthRX-affiliated physicians are U.S.-licensed and board-certified in relevant specialties such as internal medicine, emergency care, osteopathic medicine, and family medicine. Provider credentials and bios are available through the HealthRX platform. HealthRX confirms that all consultations, messaging, and record keeping are conducted through encrypted channels in compliance with HIPAA regulations. Privacy and user consent policies are explained at Health RX Wellness Support™ Adds a Preventive Layer Health RX Wellness Support™ complements prescription and telehealth services by offering educational and lifestyle tools, including: Digital health journals and medication tracking Reminder alerts for check-ins and prescription refills Curated content on nutrition, movement, and self-care Access to secure provider messaging These tools aim to reinforce adherence and increase long-term success for adults pursuing medically guided weight loss. More about the support program can be found at Verified Customer Experiences HealthRX highlights verified user reviews collected by third-party platforms: "Signing up took less than five minutes, and the process was clear." "The support staff answered every question. I already feel healthier." "After starting the treatment, I received my delivery within 48 hours." Individual experiences are unique, and HealthRX maintains a strict no-guarantee policy regarding outcomes. Additional testimonials and review information are linked from Platform Policies and Consumer Disclosures HealthRX outlines its key platform policies, including: No charge if a user does not qualify Cancellation is available anytime without penalties Refunds are processed within 24–48 hours if eligibility is not met Insurance is not required but may be used independently for reimbursement These policies are detailed in the platform's Terms of Service and FAQ sections at About HealthRX HealthRX is a U.S.-based virtual healthcare platform offering GLP-1-based weight management, online prescription access, and ongoing support through secure telehealth services. The platform includes Health RX Telehealth™, Health RX Prescription Access™, and Health RX Wellness Support™, designed to provide adults with personalized, remote wellness strategies. HealthRX is not a healthcare provider itself, but coordinates licensed services through verified clinical partners. More about the HealthRX platform can be found at Product and Contact Information Products and Services: Health RX Telehealth™ Health RX Prescription Access™ Health RX Wellness Support™ GLP-1 Medications: Ozempic®, Zepbound®, Tirzepatide®, Compounded Options Website: Contact Email: support@ +1 (208) 494-2534 Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results may vary. Consumers should consult a licensed medical provider for personalized recommendations. HealthRX does not guarantee eligibility, outcomes, or medication access. GLP-1 medications may cause serious side effects, including possible thyroid tumors. Do not use if you or a family member have a history of medullary thyroid carcinoma (MTC) or MEN 2. Compounded drugs are not FDA-approved, and their safety and effectiveness have not been evaluated by the FDA. HealthRX does not manufacture, prescribe, or dispense medication directly. All services are provided through licensed third parties. CONTACT: Email: support@ Phone: +1 (208) 494-2534Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Business
- Yahoo
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. It could soon have company, however, as others strive to develop their own treatments. Viking Therapeutics and Altimmune have exciting GLP-1 products entering phase 3 trials. 10 stocks we like better than Viking Therapeutics › Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss. In five years, the stock has soared by close to 480%, which would have turned a $20,000 investment into approximately $116,000. The GLP-1 market is still in its early growth stages, and there's plenty of room for more companies to make names for themselves. While Eli Lilly is a safe bet to invest in right now, if you want a position in stocks that may have considerably more upside in the GLP-1 market, there are two names you should take a closer look at today: Viking Therapeutics (NASDAQ: VKTX) and Altimmune (NASDAQ: ALT). The big excitement surrounding Viking is it has a GLP-1 treatment that could be a viable option for weight loss. VK2735 isn't an approved treatment yet, but it has been showing encouraging results in early-stage trials. In data released last year, a phase 2 trial showed that the drug was able to help patients lose up to 14.7% of their body weight after 13 weeks, without signs of any plateau, suggesting further weight loss could be possible. Phase 3 trials are set to begin this year. Meanwhile, Viking is also working on an oral version of the treatment, which is currently in phase 2 trials. The phase 1 data from that looked solid, with trial participants losing up to 8.2% of their body weight after 28 days. The risk with Viking is that it isn't generating revenue today, and it doesn't have any approved products. It has incurred a net loss totaling $128 million over the trailing 12 months, and there's a real possibility that those losses could deepen as it spends more on clinical trials. If VK2735 isn't successful and doesn't obtain approval from regulators, the stock could nosedive, which is the biggest concern for investors. Investors have largely looked past Viking this year, as the healthcare stock is down 35% (as of June 13), pulling its market cap down to less than $3 billion. However, if there's encouraging clinical data to come out in the future, that could trigger a rally in Viking's stock. This is a company that has a lot of upside, and if you're OK with taking on some risk, this may be a good stock to invest in a modest amount of money into. Altimmune is similar to Viking, but it's much smaller in market capitalization, worth less than $600 million. It hasn't been as popular of an option for investors, but it's an investment that may have even greater upside, given its more modest valuation. It also has a promising GLP-1 product that investors are bullish on: pemvidutide. In a phase 2 trial, participants lost an average of 15.6% of their body weight after a period of 48 weeks on the highest dosage (2.4 mg). The company doesn't have an oral version in development, but it is also testing pemvidutide as a treatment for other conditions, including metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol liver disease. Altimmune generates limited revenue (primarily coming from grants and contracts), and until and unless it obtains approval for pemvidutide, that's likely to stay this way. Over the past four quarters, its losses have totaled $90 million, and it has burned through more than $80 million just from its day-to-day operating activities. With around $150 million in cash and short-term investments, it's adequately funded, but there is high likelihood of share offerings being necessary in the future, and dilution is a real concern for investors. If pemvidutide becomes a success, Altimmune could easily double or triple in value and potentially be an acquisition target for a larger healthcare company seeking opportunities in GLP-1. There's risk with Altimmune, but there could also be tremendous upside. If you can stomach the uncertainty, you may want to consider taking a chance on the stock. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
20 hours ago
- Business
- Globe and Mail
Anti‑Obesity Drugs Market to Reach USD 100.97 Billion by 2030, Driven by GLP‑1 Incretins and Uptake of Oral Treatments
Mordor Intelligence has published a new report on the Anti‑Obesity Drugs Market, offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction Mordor Intelligence, in its latest anti‑obesity drugs market report, forecasts the market to reach from USD 25.93 billion in 2025 to USD 100.97 billion by 2030, advancing at a 31.24 % CAGR. The anti-obesity drugs market focuses on medications developed to aid in weight loss and manage obesity related conditions. Obesity is a chronic, relapsing condition associated with several health issues, including type 2 diabetes, cardiovascular diseases, sleep apnea, and certain cancers. As global obesity rates rise driven by sedentary lifestyles, poor dietary habits, and genetic factors, there is growing demand for medical interventions beyond lifestyle changes and bariatric surgery. Key Trends The anti‑obesity drugs landscape is being reshaped by several important developments: 1. GLP‑1 receptor agonists gaining dominance Gut‑hormone incretins, primarily GLP‑1 agonists, are set to expand at 33.15 % CAGR through 2030. Their strong efficacy in reducing weight and favorable safety profiles have led major pharmaceutical companies to scale up production and secure lifecycle extensions for these agents 2. Oral formulations on the rise Although injectables account for 81.3 % of the 2024 market share, oral anti‑obesity drugs are projected to grow at an impressive 36.6 % CAGR through 2030. This surge reflects patient preference for pill-based therapies and investment in oral GLP‑1 pills by developers. 3. Prescription segment maintains leadership Prescription drugs commanded 84.2 % of the anti‑obesity drugs market in 2024. Over‑the‑counter options trail behind but are gaining traction, with the prescription category still growing at a 32.56 % CAGR through 2030 4. Digital pharmacies unlocking access Retail pharmacies held 54.05 % of the market in 2024, but online pharmacies are catching up. They are expected to grow at a 34.75 % CAGR, spurred by e‑commerce ease and expanding reimbursement support. 5. Asia‑Pacific emerging fast North America remains the largest market with a 65.9 % revenue share in 2024. However, Asia‑Pacific is advancing at a robust 33.65 % CAGR, driven by rising healthcare spending and expanding obesity awareness. Market Segmentation The anti‑obesity drugs market can be segmented in multiple ways, enabling stakeholders to identify growth pockets and tailor strategies. By Mechanism of Action Peripherally acting drugs led revenue in 2024, capturing 60.10% of the market. These medications act within the digestive system, such as fat‑absorption inhibitors and appetite suppressants, reducing energy uptake or signalling fullness. Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through 2030. These therapies mimic or enhance gut hormones to regulate appetite and blood sugar. Prescription drugs held a dominant share at 84.20% in 2024. This category includes clinically validated medications with regulatory backing and reimbursement frameworks. Over‑the‑counter (OTC) drugs occupy a smaller share but are gradually gaining influence through ease of access and increasing consumer trust. By Route of Administration Injectables commanded 81.30% of the market in 2024, driven by the widespread use of injectable GLP‑1 therapies known for their strong efficacy. Oral drugs are emerging as the most dynamic segment, projected to grow at a 36.60% CAGR from 2025 to 2030, reflecting a clear patient trend toward pills over injections. By Distribution Channel Retail pharmacies made up 54.05% of market revenues in 2024, remaining the standard way for patients to obtain anti‑obesity medications. Online pharmacies are fast growing (projected 34.75% CAGR to 2030), propelled by telehealth, convenient home delivery, and evolving reimbursement policies. By Geography North America was the largest regional market, securing a 65.90% share in 2024. This dominance stems from advanced healthcare systems, approval frameworks, and strong payer support. Asia‑Pacific is the fastest expanding region, with a projected CAGR of 33.65%. Growth drivers include rising obesity awareness, healthcare investments, and broader pharmaceutical access. Key Players Roche Roche is a global pharmaceutical company that has recently entered the anti-obesity drugs market. The company has secured licensing agreements for potential weight loss candidates, signaling its interest in expanding its portfolio to include obesity treatments. Roche's expertise in biotechnology and commitment to addressing unmet medical needs position it as a noteworthy participant in the obesity care landscape. GlaxoSmithKline (GSK) GSK is a multinational healthcare company involved in the development of various therapeutic areas, including obesity. The company is exploring the potential of amylin analogs and other hormonal agents for weight management. GSK's research initiatives aim to provide patients with alternative treatment options and contribute to the advancement of obesity care. Novo Nordisk Novo Nordisk is a leading global healthcare company specializing in diabetes and obesity care. The company has developed several GLP-1 receptor agonists, including semaglutide (marketed as Ozempic and Wegovy), which have shown significant efficacy in weight management. Novo Nordisk continues to invest in research and development to expand its portfolio of anti-obesity medications and enhance patient outcomes. Currax Pharmaceuticals Currax Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of treatments for obesity. Through strategic acquisitions, such as obtaining rights to Contrave, Currax has expanded its presence in the anti-obesity drugs market. The company's focus on addressing obesity-related health issues aligns with the growing demand for effective weight management therapies. Eli Lilly and Company Eli Lilly is another major player in the anti-obesity drugs market, known for its innovative therapies. The company's GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), has demonstrated promising results in clinical trials for weight loss. Eli Lilly's commitment to obesity care is reflected in its ongoing research efforts and strategic partnerships aimed at advancing treatment options for patients. Conclusion The anti‑obesity drugs market is entering a transformative era, with expected growth from USD 25.93 billion in 2025 to USD 100.97 billion by 2030 at a 31.24 % CAGR. This growth is fuelled by the powerful clinical outcomes of GLP‑1 agonists, innovation in oral formulations, expanded access via online pharmacies, and increasing attention to obesity as a chronic disease. While North America remains the dominant market, Asia‑Pacific's rapidly growing demand offers substantial opportunities. Competition is intensifying, as established pharmaceutical companies and biotechs alike race to advance next generation therapies and diversify distribution channels. As market dynamics evolve, stakeholders should monitor: • Progress of oral GLP‑1 candidates and dual/triple‑agonists like CagriSema • Regulatory approvals and reimbursement pathways, especially in emerging regions • Competitive responses from lifecycle extensions to partnerships and acquisitions • Supply chain robustness and accessibility, particularly amid supply constraints for high‑demand drugs In sum, the anti‑obesity drugs market is poised for significant expansion, with transformative treatments and shifting delivery models likely to reshape global healthcare delivery and patient outcomes. Industry Related Reports Ozempic Market : The Ozempic Market Report is segmented by region, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report provides both value (in USD) and volume (in units) for each of these segments. Japan Oral Anti-Diabetic Drug Market: The Japan Oral Anti-Diabetic Drug Market Report is segmented by drug types, including Biguanides, Alpha-Glucosidase Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, and others, as well as end users, such as Hospitals/Clinics, Personal/Home Care Settings, and others. The report provides market size and forecasts for each segment in terms of value (USD). Get More Insights: Anti-Snoring Market: The Anti-Snoring Devices Market report segments the industry by device type, including Mandibular Advancement Devices (MAD), Tongue Stabilizing Devices (TSD), Continuous Positive Airway Pressure (CPAP) Devices, and other device types. It also segments by surgical procedures such as Uvulopalatopharyngoplasty (UPPP), Somnoplasty, Pillar Procedure, Tonsillectomy, Radiofrequency Palatoplasty, and more. Additionally, the report covers geographical segmentation. About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
